Aptevo Therapeutics Inc.
APVO · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.04 | 0.00 | 0.00 |
| FCF Yield | -315.05% | -388.64% | -91.62% | -275.45% |
| EV / EBITDA | 0.20 | -0.81 | -1.10 | -0.08 |
| Quality | ||||
| ROIC | -58.01% | -219.74% | -68.01% | -56.27% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.89 | 1.14 | 1.03 | 0.91 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -7.88% | -14.17% | -10.28% | 15.13% |
| Safety | ||||
| Net Debt / EBITDA | 0.84 | -0.35 | 0.65 | 0.57 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -5,332.04 | -5,590.33 | -3,870.00 | -5,886.67 |